626 related articles for article (PubMed ID: 20181679)
21. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Gebel JM
J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
[TBL] [Abstract][Full Text] [Related]
22. Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke.
Barlas RS; Loke YK; Mamas MA; Bettencourt-Silva JH; Ford I; Clark AB; Bowles KM; Metcalf AK; Potter JF; Myint PK
Am J Cardiol; 2018 Sep; 122(6):1085-1090. PubMed ID: 30072125
[TBL] [Abstract][Full Text] [Related]
23. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Guthrie R
Adv Ther; 2011 Jun; 28(6):473-82. PubMed ID: 21547541
[TBL] [Abstract][Full Text] [Related]
24. Antiplatelet agents and randomized trials.
Diener HC
Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
[TBL] [Abstract][Full Text] [Related]
25. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
[No Abstract] [Full Text] [Related]
26. Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
Milionis H; Ntaios G; Papavasileiou V; Spengos K; Manios E; Elisaf M; Vemmos K
J Stroke Cerebrovasc Dis; 2017 Dec; 26(12):2769-2777. PubMed ID: 28756905
[TBL] [Abstract][Full Text] [Related]
27. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Hilkens NA; Algra A; Diener HC; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Greving JP
Stroke; 2021 Oct; 52(10):3258-3265. PubMed ID: 34304604
[TBL] [Abstract][Full Text] [Related]
28. Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Hills NK; Johnston SC
Stroke; 2008 Apr; 39(4):1228-32. PubMed ID: 18323509
[TBL] [Abstract][Full Text] [Related]
29. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Albers GW; Amarenco P; Easton JD; Sacco RL; Teal P
Chest; 2008 Jun; 133(6 Suppl):630S-669S. PubMed ID: 18574275
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
Matchar DB; Samsa GP; Liu S
Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
[TBL] [Abstract][Full Text] [Related]
31. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Biller J
J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
[TBL] [Abstract][Full Text] [Related]
32. [Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Overgaard K; Poulsen TS; Husted SE
Ugeskr Laeger; 2007 Oct; 169(40):3379-82. PubMed ID: 17953858
[TBL] [Abstract][Full Text] [Related]
33. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
Diedler J; Ahmed N; Sykora M; Uyttenboogaart M; Overgaard K; Luijckx GJ; Soinne L; Ford GA; Lees KR; Wahlgren N; Ringleb P
Stroke; 2010 Feb; 41(2):288-94. PubMed ID: 20056933
[TBL] [Abstract][Full Text] [Related]
34. Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
Aw D; Sharma JC
Postgrad Med J; 2012 Jan; 88(1035):34-7. PubMed ID: 22121248
[TBL] [Abstract][Full Text] [Related]
35. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
[TBL] [Abstract][Full Text] [Related]
36. Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
Burke JP; Sander S; Shah H; Zarotsky V; Henk H
Curr Med Res Opin; 2010 May; 26(5):1023-30. PubMed ID: 20199138
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Malloy RJ; Kanaan AO; Silva MA; Donovan JL
Clin Ther; 2013 Oct; 35(10):1490-1500.e7. PubMed ID: 24139421
[TBL] [Abstract][Full Text] [Related]
38. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Sprigg N; Gray LJ; England T; Willmot MR; Zhao L; Sare GM; Bath PM
PLoS One; 2008 Aug; 3(8):e2852. PubMed ID: 18682741
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
[TBL] [Abstract][Full Text] [Related]
40. Antiplatelet drugs for ischemic stroke prevention.
Leys D; Balucani C; Cordonnier C
Cerebrovasc Dis; 2009; 27 Suppl 1():120-5. PubMed ID: 19342841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
